Amylyx Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
AMLX$30.21+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenues: | |||
| Product revenue, net | $380,786 | $22,230 | $— |
| Grant revenue | — | — | 285 |
| Total revenues | 380,786 | 22,230 | 285 |
| Operating expenses: | |||
| Cost of sales | 25,441 | 2,993 | — |
| Research and development | 128,187 | 93,450 | 44,040 |
| Selling, general and administrative | 188,356 | 127,128 | 38,933 |
| Total operating expenses | 341,984 | 223,571 | 82,973 |
| Income (loss) from operations | 38,802 | (201,341) | (82,688) |
| Other income (expense), net: | |||
| Interest income | 16,155 | 4,291 | 36 |
| Change in fair value of convertible notes | — | — | (5,228) |
| Other expense, net | (660) | (551) | (51) |
| Total other income (expense), net | 15,495 | 3,740 | (5,243) |
| Income (loss) before income taxes | 54,297 | (197,601) | (87,931) |
| Provision for income taxes | 5,026 | 774 | — |
| Net income (loss) | $49,271 | $(198,375) | $(87,931) |
| Net income (loss) per share | |||
| Basic | $0.73 | $(3.39) | $(13.35) |
| Diluted | $0.70 | $(3.39) | $(13.35) |
| Weighted-average shares used in computing net income (loss) per share | |||
| Basic | 67,234,465 | 58,495,587 | 6,586,349 |
| Diluted | 69,991,340 | 58,495,587 | 6,586,349 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.